Soluble HLA Class I and Fas Ligand Molecules in Blood Components and their Role in the Immunomodulatory Effects of Blood Transfusions

References

• Billingham R.E., Brent L., Medawar P.B. “Actively acquired tolerance” of foreign cells. Nature 1953; 172: 603–606
   PubMed Web of Science ®Google Scholar
• Opelz G., Mickey M.R., Terasaki P. (1978) Effect of blood transfusions on subsequent kidney transplants. Transplantation Proceedings 1973; 5:253–255. 1973
   Google Scholar
• Persijn G.G., Cohen B., Lansbergen Q., Van Rood J.J. Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in The Netherlands. Transplantation 1979; 28: 396–401
   PubMed Web of Science ®Google Scholar
• Gatenby P.A., Cameron K., Simes R.J., Adelstein S., Ben-Net M.J., Yonsen R.P., Shearman R.P., Stewart G.J., Whittle M., Doran T.J. Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes: results of a controlled trial. American Journal of Reproductive Immunology 1993; 29: 88–94
   PubMed Web of Science ®Google Scholar
• Dzik S., Blajchman M.A., Blumberg N., Kirkley S.A., Heal J.M., Wood K. Current research on the immunomodulatory effect of allogeneic blood transfusion. Vox Sanguinis 1996; 70: 187–190
   PubMed Web of Science ®Google Scholar
• Jonker M., Persijn G.G., Parlevliet J., Frederiks E., Van Rood J.J. The influence of previous immunization on skin graft survival. Transplantation 1979; 27: 250–253
   PubMed Web of Science ®Google Scholar
• Blajchman M.A. Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: do we have the answers yet. Transfusion 1997; 37: 121–125
   PubMed Web of Science ®Google Scholar
• Vamvakas E.C., Moore S.B. Blood transfusion and postoperative septic complications. Transfusion 1994; 34: 714–727
   PubMed Web of Science ®Google Scholar
• Lapierre V., Auperin A., Tiberghien P. Transfusion-induced immunomodulation following cancer surgery: fact or fiction?. Journal of the National Cancer Institute 1998; 90: 573–580
   PubMed Web of Science ®Google Scholar
• Houbiers J.G., van de Velde C.J., van de Watering L.M., Hermans J., Schreuder S., Bijnen A.B., Pahlplatz P., Eeftinck Schattenkerk M., Wobbes T., de Vries J.E., Klements-Chitsch P., van de Maas A.H., Brand A. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study. Transfusion 1997; 37: 126–134
   PubMed Web of Science ®Google Scholar
• Busch O.R., Hop W.C., Hoynck van Papendrecht M.A., Marquet R.L., Jeekel J. Blood transfusions and prognosis in colorectal cancer. New England Journal of Medicine 1993; 328: 1372–1376
   PubMed Web of Science ®Google Scholar
• van de Watering L.M.G., Hermans J., Houbiers J.G., van den Broek P.J., Bouter H., Boer R, Harvey M.S., Huys-Mans H.A., Brand A. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery. A randomized clinical trial. Circulation 1998; 97: 562–568
   PubMed Web of Science ®Google Scholar
• Natali P.G., Bigotti A., Nicotra M.R., Viora M., Manfredi D., Ferrone S. Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Research 1984; 44: 4679–4687
   PubMed Web of Science ®Google Scholar
• Lee J.S. Regulation of HLA class II gene expression. Immunobiology of HLA, B. Dupont. Springer-Verlag, New York 1987; 49–62
   Google Scholar
• Van Rood J.J., van Leeuwen A., van Santen M.C.T. Anti HL-A2 inhibitor in normal human serum. Nature 1970; 226: 366–367
   PubMed Web of Science ®Google Scholar
• Charlton R.K., Zmijewski CM. Soluble HL-A7 antigen: localization in the P-lipoprotein fraction of human serum. Science 1970; 170: 636–637
   PubMed Web of Science ®Google Scholar
• Allison J.P., Pellegrino M.A., Ferrone S., Callahan G.N., Reisfeld R.A. Biologic and chemical characterization of HLA antigens in human serum. Journal of Immunology 1977; 118: 1004–1009
   PubMed Web of Science ®Google Scholar
• Dobbe L.M.E., Stam N.J., Neefjes J.J., Giphart M.J. Biochemical complexity of serum HLA class I molecules. Immunogenetics 1988; 27: 203–210
   PubMed Web of Science ®Google Scholar
• Krangel M.S. Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. Journal of Experimental Medicine 1986; 163: 1173–1190
   PubMed Web of Science ®Google Scholar
• Krangel M.S. Two forms of HLA Class I molecules in human plasma. Human Immunology 1987; 20: 155–165
   PubMed Web of Science ®Google Scholar
• Wilson B.S., Indiveri R, Pellegrino M.A., Ferrone S. Production and characterization of DR xenoantisera: use for detection of serum DR antigens. Journal of Immunology 1979; 122: 1967–1971
   PubMed Web of Science ®Google Scholar
• Puppo F., Brenci S., Lanza L., Bosco O., Imro M.A., Scudeletti M., Indiveri F., Ferrone S. Increased level of serum HLA Class I antigens in HIV infection. Correlation with disease progression. Human Immunology 1994; 40: 259–266
   PubMed Web of Science ®Google Scholar
• Hagihara M., Shimura T., Yamamoto K., Sujirachato K., Tsuji S., Yamamura M., Tsuji K. Clinical significance of serum soluble HLA class I antigens in systemic lupus erythematosus. Tokai Journal of Experimental and Clinical Medicine 1993; 18: 61–64
   PubMedGoogle Scholar
• Zavazava N., Bottcher H., Muller-Ruchholtz W. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 1993; 42: 20–26
   PubMed Web of Science ®Google Scholar
• Rhynes K.V., McDonald J.C., Gelder KB., Aultman D.F., Hayes J.M., McMillan R.W., Mancini M.C. Soluble HLA Class I in the serum of transplant recipients. Annals of Surgery 1993; 217: 485–491
   PubMed Web of Science ®Google Scholar
• Davies H., Pollard S.G., Calne R.Y. Soluble HLA antigens in the circulation of liver graft recipients. Transplantation 1989; 41: 524–527
   Google Scholar
• Puppo R, Pellicci R., Brenci S., Nocera A., Morelli A., Dardano G., Bertocchi M., Antonucci A., Ghio M., Scudeletti M., Barocci S., Valente U., Indiveri F. HLA Class-I-soluble antigen serum levels in liver transplantation. A predictor marker of acute rejection. Human Immunology 1994; 40: 166–170
   PubMed Web of Science ®Google Scholar
• DeVito-Haynes L.D., Jankowska-Gan E., Sollinger H.W., Knechtle S.J., Burlingham W.J. Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific, soluble HLA Class I. Human Immunology 1994; 40: 191–201
   PubMed Web of Science ®Google Scholar
• Pollard S.G., Davies H.ff.S., Calne R.Y. Perop-erative appearance of serum class I antigen during liver transplantation. Transplantation 1990; 49: 659–660
   PubMed Web of Science ®Google Scholar
• Westhoff U., Doxiadis I., Beelen D.W., Schaefer U.W., Grosse-Wilde H. Soluble HLA Class I concentrations and GVHD after allogeneic marrow transplantation. Transplantation 1989; 48: 890–893
   PubMed Web of Science ®Google Scholar
• Puppo F, Brenci S., Ghio M., Bignardi D., Contini P., Bacigalupo A., Van Lint M.T., Scudeletti M., Ferrone S., Indiveri F. Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD. Bone Marrow Transplantation 1996; 17: 753–758
   Google Scholar
• Hausmann R., Zavazava N., Steinmann J., Muller-Ruchholtz W. Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL). Clinical and Experimental Immunology 1993; 91: 183–188
   PubMed Web of Science ®Google Scholar
• Parham P., Clayberger C., Zorn S.L., Ludwig D.S., School-Nik G.K., Krensky A.M. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the 012 domain of HLA-A2. Nature 1987; 325: 625–628
   PubMed Web of Science ®Google Scholar
• Schneck J., Lee Maloy W., Coligan J.E., Margulies D.H. Inhibition of an allospecific T cell hybridoma by soluble class I proteins: estimation of the affinity of a T cell receptor for MHC. Cell 1989; 56: 47–56
   PubMed Web of Science ®Google Scholar
• Puppo F, Brenci S., Montinaro E., Lanza L., Contini P., Scudeletti M., Indiveri F. Inhibition of alloreactive cytotoxic T cell activity by HIV-positive sera: potential role of circulating soluble HLA Class I molecules. AIDS Research and Human Retroviruses 1994; 10: 1061–1064
   PubMed Web of Science ®Google Scholar
• Nicolle M.W., Nag B., Sharma S.D., Willcox N., Vincent A., Ferguson D.J.P., Newsom-Davis J. Specific tolerance to an acetylcoline receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. Journal of Clinical Investigation 1994; 93: 1361–1369
   PubMed Web of Science ®Google Scholar
• Zavazava N., Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nature Medicine 1996; 2: 1005–1010
   PubMed Web of Science ®Google Scholar
• Puppo F, Contini P., Ghio M., Brenci S., Scudeletti M., Filaci G., Ferrone S., Indiveri F. Soluble human major histocompatibility complex Class I molecules induce soluble Fasligand secretion and trigger apoptosis in activated CD8+ Fas(CD95)+ T lymphocytes. International Immunology, in press
   PubMed Web of Science ®Google Scholar
• Sayegh M.H., Carpenter C.B. Role of indirect allorecognition in allograft rejection. International Review of Immunology 1996; 13: 221–229
   PubMedGoogle Scholar
• Nagata S. Fas and Fas ligand: a death factor and its receptor. Advances in Immunology 1994; 57: 129–144
   PubMed Web of Science ®Google Scholar
• Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of the Fas ligand in cells of T cell lineage. Journal of Immunology 1995; 154: 3806–3813
   PubMed Web of Science ®Google Scholar
• Liles W.C., Kiener P.A., Ledbetter J.A., Aruffo A., Klebanoff S.J. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. Journal of Experimental Medicine 1996; 184: 429–440
   PubMed Web of Science ®Google Scholar
• Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A.H., Nagata S. Fas ligand in human serum. Nature Medicine 1996; 2: 317–322
   PubMed Web of Science ®Google Scholar
• van Parijs L., Abbas A.K. Role of Fas-mediated cell death in the regulation of immune responses. Current Opinion in Immunology 1996; 8: 355–361
   PubMed Web of Science ®Google Scholar
• Westhoff U., Grosse Wilde H. Soluble HLA class I and class II concentrations in factor VIII and PCC preparations. Vox Sanguinis 1995; 68: 73–76
   PubMed Web of Science ®Google Scholar
• Grosse-Wilde H., Blasczyk R., Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 1992; 39: 74–77
   PubMed Web of Science ®Google Scholar
• Blasczyk R., Westhoff U., Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789–790
   PubMed Web of Science ®Google Scholar
• Santoso S., Kiefel V, Volz H., Mueller-Eckhardt C. Quantitation of soluble HLA class I antigen in albumin and immunoglobulin preparations for intravenous use by solid-phase immunoassay. Vox Sanguinis 1992; 62: 29–33
   PubMed Web of Science ®Google Scholar
• Ghio M., Contini P., Mazzei C., Brenci S., Barberis G., Filaci G., Indiveri F, Puppo F. Soluble HLA class I, HLA class II and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusion. Blood 1999; 93: 1770–1777
   PubMed Web of Science ®Google Scholar
• Kao K.J. Plasma and platelet HLA in normal individuals: quantitation by competitive enzyme-linked immunoassay. Blood 1987; 70: 282–286
   PubMed Web of Science ®Google Scholar
• Liebert M., Aster R.H. Expression of HLA-B12 on platelets, on lymphocytes and in serum: a quantitative study. Tissue Antigens 1977; 9: 199–208
   PubMed Web of Science ®Google Scholar
• Lalezari P., Driscoll A.M. Ability of thrombocytes to acquire HLA specificity from plasma. Blood 1982; 59: 167–170
   PubMed Web of Science ®Google Scholar
• Everett E.T., Kao K.J., Scornik J.C. Class I HLA molecules on human erythrocytes. Quantitation and transfusion effects. Transplantation 1987; 44: 123–129
   PubMed Web of Science ®Google Scholar
• Goodnough L.T., Monk T.G., Brecher M.E. Autologous blood procurement in the surgical setting: lessons to be learned in the last 10 years. Vox Sanguinis 1996; 71: 133–141
   PubMed Web of Science ®Google Scholar
• Heiss M.M., Mempel W., Delanoff C., Jauch K.W., Gabka C., Mempel M., Dieterich H.J., Heissener H.J., Schildberg F.W. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. Journal of Clinical Oncology 1994; 12: 1859–1867
   PubMed Web of Science ®Google Scholar
• American Association of Blood Banks. BPAC recommends universal leukoreduction. American Association of Blood Banks News Briefs 1998; 20: 16
   Google Scholar
• Kliiter H., Schlenke P., Muller-Steinhardt M., Paulsen M., Kirchner H. Impact of buffy coat storage on the generation of inflammatory cytokines and platelet activation. Transfusion 1998; 37: 362–367
   Web of Science ®Google Scholar
• Shanwell A., Kristiansson M., Remberger M., Ringden O. Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion 1998; 37: 678–684
   Web of Science ®Google Scholar
• Mincheff M. Changes in donor leukocytes during blood storage. Implications on post-transfusion lmmunomodulation and transfusion-associated GVHD. Vox Sanguinis 1998; 74: 189–200
   PubMed Web of Science ®Google Scholar
• Dzik S., Szuflad P., Eaves S. HLA antigens on leukocyte fragments and plasma proteins. Prestorage leukoreduction by filtration. Vox Sanguinis 1998; 66: 104–111
   Google Scholar
• Salter R.D., Benjamin R.J., Wesley P.K., Buxton S.E., Garret T.P.J., Clayberger C., Krensky A.M., Norment A.M., Littman D.R., Parham P. A binding site of the T-cell co-receptor CD8 on the α3 domain of HLA-A2. Nature 1990; 345: 41–46
   PubMed Web of Science ®Google Scholar
• Ju S.T., Panka D.J., Cui H., Ettinger R., El-Khatib M., Sherr D.H., Stanger B.Z., Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444–448
   PubMed Web of Science ®Google Scholar